FIELD: immunology, medicine.
SUBSTANCE: claimed recombinant antibody (Ab) has at least constant regions in heavy and light chains representing human Ab regions. Said At inhibits bonding of integrine recognizing RGD and SVVYGLR sequences to integrine or fragment thereof. Also disclosed are nucleotide sequences (NS) encoding heavy and light chains of recombinant Ab as well as expression vectors containing respective NS. Described are host cell for Ab production, transformed with two vectors for expression of Ab heavy and light chains and method for abovementioned host cell application to produce recombinant Ab. Ab of present invention is useful in diagnosis and treatment of autoimmune diseases, rheumatism and rheumatoid arthritis.
EFFECT: therapeutic methods of increased efficiency.
45 cl, 14 tbl, 28 ex
| Title | Year | Author | Number |
|---|---|---|---|
| HUMANISED HUMAN OSTEOPONTIN ANTIBODY | 2007 |
|
RU2429016C2 |
| ANTIBODY AGAINST OSTEOPONTIN AND ITS USING | 2002 |
|
RU2299888C2 |
| IMPROVED HUMANISED ANTIBODY TO HUMAN α9-INTEGRIN | 2009 |
|
RU2503720C2 |
| HUMANISED ANTIBODIES TO Toll-LIKE RECEPTORS 2 AND THEIR APPLICATIONS | 2010 |
|
RU2563344C2 |
| CHIMERIC AND HUMANISED INTEGRIN α5β1 ANTIBODIES MODULATING ANGIOGENESIS | 2003 |
|
RU2346701C2 |
| PEPTIDE OR PEPTIDE COMPLEX BINDING TO alpha2- INTEGRIN, METHODS FOR PRODUCTION AND USE THEREOF | 2011 |
|
RU2588668C2 |
| MYL9 ANTIBODY | 2017 |
|
RU2741802C2 |
| INTEGRIN ανβ8 NEUTRALISING ANTIBODIES | 2011 |
|
RU2565539C2 |
| SILENT ANTI-CD28-ANTIBODY AND THEIR APPLYING | 2001 |
|
RU2261723C2 |
| HUMANISED ANTIBODIES AGAINST TNFα | 2012 |
|
RU2549700C1 |
